151 related articles for article (PubMed ID: 28527603)
21. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
Lieberman MR; Liebman TN; Alapati U; Khachemoune A
Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756476
[TBL] [Abstract][Full Text] [Related]
22. Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study.
Hattori Y; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Terabe K; Yabe Y; Miyake H; Kato T; Takagi H; Hayashi M; Ito T; Kanayama Y; Oguchi T; Takahashi N; Ishikawa H; Funahashi K; Ishiguro N
J Rheumatol; 2016 Aug; 43(8):1475-9. PubMed ID: 27307531
[TBL] [Abstract][Full Text] [Related]
23. Immediate local and systemic hypersensitivity due to etanercept and adalimumab.
Hansel K; Bianchi L; Tramontana M; Balato A; Scala E; Brozzi J; Stingeni L
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):726-727. PubMed ID: 30006049
[No Abstract] [Full Text] [Related]
24. Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment.
Ikuta K; Ota Y; Kuroki S; Matsumoto Y; Senda E; Mukohara S; Takahashi S; Monden K; Fukuda A; Seno H; Kumagai S; Shio S
Intern Med; 2020 Mar; 59(6):849-853. PubMed ID: 31761884
[TBL] [Abstract][Full Text] [Related]
25. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.
Ray M; Curtis JR; Baddley JW
Ann Rheum Dis; 2014 Jul; 73(7):1429-30. PubMed ID: 24618264
[No Abstract] [Full Text] [Related]
26. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
27. Tuberculous peritonitis during infliximab therapy.
Verhave JC; van Altena R; Wijnands MJ; Roerdink HT
Neth J Med; 2008 Feb; 66(2):77-80. PubMed ID: 18292611
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumour necrosis factor α-induced lupus erythematosus panniculitis.
Durand AL; Goussot JF; Thiolat D; Taieb A; Marie J; Seneschal J; Darrigade AS
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):e318-e319. PubMed ID: 28045205
[No Abstract] [Full Text] [Related]
29. A 74-year-old female with recurrent infections receiving methotrexate for rheumatoid arthritis.
Wijetilleka S; Chander S; Karim MY
Rheumatology (Oxford); 2019 Jul; 58(7):1309-1310. PubMed ID: 30879043
[No Abstract] [Full Text] [Related]
30. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
[TBL] [Abstract][Full Text] [Related]
31. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
[TBL] [Abstract][Full Text] [Related]
32. Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?
Tan Y; Kavaklieva S; Wood F
Rheumatology (Oxford); 2021 Aug; 60(8):e288-e289. PubMed ID: 33836074
[No Abstract] [Full Text] [Related]
33. Miliary tuberculosis and herpes pharyngitis after a trip to a developing country: dangers of biologics.
Patel S; Weaver MD; Roy S
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30279249
[TBL] [Abstract][Full Text] [Related]
34. [Infections during antirheumatic treatment].
Kneitz C
Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1593-5. PubMed ID: 25076314
[No Abstract] [Full Text] [Related]
35. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):e3-e42. PubMed ID: 30137552
[No Abstract] [Full Text] [Related]
36. Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis.
Pereira ICP; Sousa NCF; Pereira DMS; Mendes SJF; Muniz TF; Colares VLP; Silva BLR; Monteiro CRAV; Martins MMRS; Fernandes AMR; Fernandes ES
An Acad Bras Cienc; 2018 Aug; 90(2 suppl 1):2161-2166. PubMed ID: 29947664
[TBL] [Abstract][Full Text] [Related]
37. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):220-226. PubMed ID: 30137623
[No Abstract] [Full Text] [Related]
38. Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection.
Nagafuchi Y; Shoda H; Fujio K; Ishii S; Sugiyama H; Yamamoto K
Mod Rheumatol; 2013 Sep; 23(5):1013-7. PubMed ID: 22911136
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab-induced photosensitivity and oral erosions in rheumatoid arthritis.
Thakur V; Bakshi S; Bishnoi A
Postgrad Med J; 2020 Oct; 96(1140):631-632. PubMed ID: 31896550
[No Abstract] [Full Text] [Related]
40. Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.
Harigai M; Tsuchiya T; Kawana K; Kurimoto S
Mod Rheumatol; 2018 Jan; 28(1):30-38. PubMed ID: 28388293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
